Ultragenyx (RARE)

NASDAQ
62.65
+2.99(+5.01%)
After Hours
62.65
0.00(0.00%)
- Real-time Data
  • Volume:
    455,255
  • Day's Range:
    58.65 - 63.28
  • 52 wk Range:
    45.20 - 104.38

RARE Overview

Prev. Close
59.66
Day's Range
58.65-63.28
Revenue
331.95M
Open
59.84
52 wk Range
45.2-104.38
EPS
-6.86
Volume
455,255
Market Cap
4.38B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
562,843
P/E Ratio
-
Beta
1.34
1-Year Change
-33.5%
Shares Outstanding
69,930,191
Next Earnings Date
Aug 04, 2022
What is your sentiment on Ultragenyx?
or
Market is currently closed. Voting is open during market hours.

Ultragenyx News

Ultragenyx Analysis

Ultragenyx Company Profile

Ultragenyx Company Profile

Employees
1119

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyBuySell
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong BuyStrong Sell
SummarySellStrong BuyStrong BuyStrong BuyStrong Sell
  • DUUUMP!!!! Illusion!!!
    0